Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 35 28 versus LO BLISOVI FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 35 28 versus LO BLISOVI FE.
DEMULEN 1/35-28 vs LO-BLISOVI FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation; norethindrone induces endometrial changes, increasing cervical mucus viscosity.
One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo tablets.
None Documented
None Documented
Ethinyl estradiol: 17.4 ± 5.6 h (terminal); norethindrone: 10.9 ± 1.6 h (terminal); clinically, steady-state achieved within 5-7 days.
Terminal elimination half-life: 15-18 hours for ethinyl estradiol; clinical context: supports once-daily dosing
Renal 50% (metabolites), fecal 50% (biliary elimination of conjugates).
Renal (approximately 60% as metabolites, 10-15% as unchanged drug); fecal (about 20-30%)
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive